戊乙奎醚联合依达拉奉治疗对急性脑梗塞患者血清TNF-α和NDS的影响

摘要

Objective To explore the effects of Penehyclidine combined with Edaravone on tumor necrosis factor-α (TNF-α) and neurologic impairment score (NDS) in patients with acute cerebral infarction. Methods Six-ty-eight patients with acute cerebral infarction were selected randomly in our hospital from March in 2011 to March in 2013. According to the treatment methods, they were divided into observation group and control group equally with 34 cases in each group. The control group was treated with Edaravone, while the observation group was given combined Penehyclidine and Edaravone. TNF-αlevels and NDS were evaluated before and after treatment, and then compared be-tween the two groups. Results The total effective rate in the observation group was significantly higher than that in the control group (88.24%vs 67.65%, P<0.05). In the two groups, TNF-αand NDS after treatment were lower than those before treatment with statistically significant differences [(20.78±2.38) ng/ml vs (28.01±2.46) ng/ml, (15.02±3.04) vs (19.37±2.87), respectively, P<0.05]. Conclusion Penehyclidine combined with Edaravone had good clinical effect in patients with acute cerebral infarction, which significantly reduced TNF-αand NDS and is worthy of clinical application.%目的：探讨戊乙奎醚联合依达拉奉治疗急性脑梗塞对患者的血清肿瘤坏死因子(TNF-α)和神经功能缺损评分(NDS)的影响。方法选取2011年3月至2013年3月在我院诊治的急性脑梗塞患者68例，根据治疗方法随机分为观察组和对照组，每组34例，对照组患者在常规治疗方法的基础上给予依达拉奉治疗，观察组患者则在常规治疗的基础上给予依达拉奉联合戊乙奎醚治疗。观察两组患者的治疗效果及其治疗前后患者的TNF-α水平和NDS的变化。结果观察组患者的总显效率为88.24%(30/34)，高于对照组的67.65%(23/34)，差异具有统计学意义(P<0.05)；两组患者治疗后血清TNF-α水平和NDS均低于治疗前，差异具有统计学意义(P<0.05)。观察组患者治疗后TNF-α为(20.78±2.38) ng/ml，明显低于对照组的(28.01±2.46) ng/ml，差异具有统计学意义(P<0.05)。观察组患者治疗后的NDS为(15.02±3.04)分，明显低于对照组的(19.37±2.87)分，差异具有统计学意义(P<0.05)。结论戊乙奎醚联合依达拉奉治疗急性脑梗塞患者具有良好的临床效果，可显著降低血清TNF-α水平和NDS，值得临床推广应用。